Aclaris Therapeutics, Inc. Investing Cash Flow
Aclaris Therapeutics, Inc. (ACRS) reported Investing Cash Flow of -$20.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $10.26M, a 103.35% increase year-over-year.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$30.93M, a 261.79% decline year-over-year.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $10.37M.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $13.83M, a 394.81% increase year-over-year.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $48.37M.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$69.77M, a 250.95% decline from fiscal 2023.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $46.22M, a 266.01% increase from fiscal 2022.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $12.63M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$20.67M 10-Q · filed 2026-08-06 | -$10.30M derived: sum of 3 quarters · filed 2026-08-06 | $3.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$30.93M 10-Q · filed 2026-05-07 | -$20.56M derived: sum of 2 quarters · filed 2026-05-07 | -$6.73M derived: sum of 3 quarters · filed 2026-05-07 | -$1.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.20M derived: sum of 2 quarters · filed 2026-02-26 | $29.25M derived: sum of 3 quarters · filed 2026-08-06 | $48.37M 10-K · filed 2026-02-26 |
| 2025-09-30 | $13.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.88M derived: sum of 2 quarters · filed 2026-08-06 | $38.00M 10-Q · filed 2025-11-06 | -$50.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $24.17M 10-Q · filed 2026-08-06 | -$64.56M derived: sum of 3 quarters · filed 2026-08-06 | -$61.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $19.12M 10-Q · filed 2026-05-07 | -$69.60M derived: sum of 2 quarters · filed 2026-05-07 | -$66.81M derived: sum of 3 quarters · filed 2026-05-07 | -$67.48M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$88.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$85.93M derived: sum of 2 quarters · filed 2026-02-26 | -$86.60M derived: sum of 3 quarters · filed 2026-02-26 | -$69.77M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.12M derived: sum of 2 quarters · filed 2025-11-06 | $18.95M 10-Q · filed 2025-11-06 | $26.50M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$674.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $16.16M 10-Q · filed 2025-08-07 | $23.71M derived: sum of 3 quarters · filed 2025-08-07 | $56.24M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $16.83M 10-Q · filed 2025-05-08 | $24.38M derived: sum of 2 quarters · filed 2025-05-08 | $56.92M derived: sum of 3 quarters · filed 2025-05-08 | $37.26M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $40.08M derived: sum of 2 quarters · filed 2025-02-27 | $20.42M derived: sum of 3 quarters · filed 2025-02-27 | $46.22M 10-K · filed 2025-02-27 |
| 2023-09-30 | $32.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $12.87M derived: sum of 2 quarters · filed 2024-11-06 | $38.67M 10-Q · filed 2024-11-06 | $41.37M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$19.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $6.14M 10-Q · filed 2024-08-07 | $8.84M derived: sum of 3 quarters · filed 2024-08-07 | $10.05M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $25.80M 10-Q · filed 2024-05-07 | $28.50M derived: sum of 2 quarters · filed 2024-05-07 | $29.72M derived: sum of 3 quarters · filed 2024-05-07 | $8.49M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.92M derived: sum of 2 quarters · filed 2024-02-27 | -$17.30M derived: sum of 3 quarters · filed 2024-02-27 | $12.63M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$20.01M derived: sum of 2 quarters · filed 2023-11-06 | $9.93M 10-Q · filed 2023-11-06 | $750.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$21.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $8.71M 10-Q · filed 2023-08-07 | -$467.00K derived: sum of 3 quarters · filed 2024-02-27 | -$38.14M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $29.93M 10-Q · filed 2023-05-08 | $20.76M derived: sum of 2 quarters · filed 2024-02-27 | -$16.92M derived: sum of 3 quarters · filed 2024-02-27 | -$62.39M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$9.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$46.85M derived: sum of 2 quarters · filed 2024-02-27 | -$92.32M derived: sum of 3 quarters · filed 2024-02-27 | -$167.63M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$37.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$83.14M derived: sum of 2 quarters · filed 2022-11-08 | -$158.46M 10-Q · filed 2022-11-08 | -$160.76M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$45.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$120.78M 10-Q · filed 2022-08-03 | -$123.09M derived: sum of 3 quarters · filed 2023-02-23 | -$117.85M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$75.31M 10-Q · filed 2022-05-10 | -$77.62M derived: sum of 2 quarters · filed 2023-02-23 | -$72.38M derived: sum of 3 quarters · filed 2023-02-23 | -$82.87M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.93M derived: sum of 2 quarters · filed 2023-02-23 | -$7.55M derived: sum of 3 quarters · filed 2023-02-23 | $6.39M 10-K · filed 2023-02-23 |
| 2020-09-30 | $5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$5.25M derived: sum of 2 quarters · filed 2021-11-02 | $8.69M 10-Q · filed 2021-11-02 | $65.13M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$10.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.46M 10-Q · filed 2021-08-05 | $59.89M derived: sum of 3 quarters · filed 2022-02-24 | $81.57M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $13.94M 10-Q · filed 2021-05-07 | $70.38M derived: sum of 2 quarters · filed 2022-02-24 | $92.05M derived: sum of 3 quarters · filed 2022-02-24 | $111.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $56.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $78.11M derived: sum of 2 quarters · filed 2022-02-24 | $97.06M derived: sum of 3 quarters · filed 2022-02-24 | $105.68M 10-K · filed 2022-02-24 |
| 2019-09-30 | $21.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $40.63M derived: sum of 2 quarters · filed 2020-11-04 | $49.24M 10-Q · filed 2020-11-04 | -$21.27M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $18.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $27.57M 10-Q · filed 2020-08-07 | -$42.94M derived: sum of 3 quarters · filed 2021-02-25 | -$32.54M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $8.62M 10-Q · filed 2020-05-07 | -$61.89M derived: sum of 2 quarters · filed 2021-02-25 | -$51.50M derived: sum of 3 quarters · filed 2021-02-25 | -$38.21M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$70.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$60.11M derived: sum of 2 quarters · filed 2021-02-25 | -$46.83M derived: sum of 3 quarters · filed 2021-02-25 | $9.37M 10-K · filed 2021-02-25 |
| 2018-09-30 | $10.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $23.68M derived: sum of 2 quarters · filed 2019-11-07 | $79.87M 10-Q · filed 2019-11-07 | $58.31M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $13.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $69.48M 10-Q · filed 2019-08-08 | $47.91M derived: sum of 3 quarters · filed 2020-02-25 | $8.06M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $56.19M 10-Q · filed 2019-05-08 | $34.63M derived: sum of 2 quarters · filed 2020-02-25 | -$5.23M derived: sum of 3 quarters · filed 2020-02-25 | -$5.46M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | -$21.57M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$61.42M derived: sum of 2 quarters · filed 2020-02-25 | -$61.65M derived: sum of 3 quarters · filed 2020-02-25 | -$55.69M 10-K · filed 2020-02-25 |
| 2017-09-30 | -$39.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$40.08M derived: sum of 2 quarters · filed 2018-11-06 | -$34.13M 10-Q · filed 2018-11-06 | -$111.94M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | -$226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $5.73M 10-Q · filed 2018-08-03 | -$72.09M derived: sum of 3 quarters · filed 2019-03-18 | -$76.22M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | $5.96M 10-Q · filed 2018-05-08 | -$71.86M derived: sum of 2 quarters · filed 2019-03-18 | -$75.99M derived: sum of 3 quarters · filed 2019-03-18 | |
| 2016-12-31 | -$77.82M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$81.94M derived: sum of 2 quarters · filed 2019-03-18 | -$61.90M 10-K · filed 2019-03-18 | |
| 2016-09-30 | -$4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $15.91M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $20.04M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | -$76.95M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |